Another clean interim safety review of RhoVac’s clinical phase IIb study in prostate cancer
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on December 9[th], 2021, that its Data & Safety Monitoring Committee (DSMC) has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac. All patients have now been recruited into the study. The safety profile of RV001 (onilcamotide) was considered excellent, and the DSMC concluded that the trial can continue without modifications.RhoVac started the clinical phase IIb trial (BRaVac) with the company’s drug candidate, RV001, (onilcamotide) late 2019, in prostate